References
Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative toconventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 1998 91: 756–763
Giralt S, Thall PF, Khouri I et al. Melphalan and purineanalog-containing preparative regimens: reduced-intensityconditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation Blood 2001 97: 631–637
Kottaridis PD, Milligan DW, Chopra R et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation Blood 2000 96: 2419–2425
Chakrabarti S, Kottaridis P, Ogormon P et al. High incidence of early and late CMV infection and delayed immune reconstitution after allogeneic transplants with nonmyeloablative conditioning using Campath (anti-CD52 antibody) Blood 2000 96: 525a (Abstr.)
Craddock C, Bardy P, Kreiter S et al. Engraftment of T cell-depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimen Br J Haematol 2000 111: 797–800
Hale G, Jacobs P, Wood L et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells Bone Marrow Transplant 2000 26: 69–76
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chakrabarti, S., McDonald, D. & Milligan, D. T cell-depleted nonmyeloablative stem cell transplantation: what is the optimum balance between the intensity of host conditioning and the degree of T cell depletion of the graft?. Bone Marrow Transplant 28, 313–314 (2001). https://doi.org/10.1038/sj.bmt.1703117
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703117
- Springer Nature Limited